PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma
PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma
Not yet recruiting · NCT06125223 · Registry updated 2023-11-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Not yet recruiting | Not stated | 2023-11-09 | NCT06125223 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Xijing Hospital | 177 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||